JPRN-UMIN000029076Recruiting未知
Development of surrogate end-point biomarkers for chronic fatigue and myalgic encephalmyelitis/chronic fatigue syndrome ( ME/CFS) - Development of surrogate biomarkers for ME/CFS
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Osaka City University
- Enrollment
- 120
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Others,meta-analysis etc
Eligibility Criteria
- Ages
- 20years-old to 60years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Pregnant women, those who are likely to become pregnant, those who are breastfeeding 2) Person who has metal, pacemaker in the body by surgery etc. 3) Claudophobia 4) Persons who have a history of feeling sick during blood sampling 5) Persons who are experiencing psychiatric diseases before suffering chronic fatigue syndrome 6) Person who has fatigue performance status less than 4 7) A person who falls under the exclusionary disorder in ME/CFS clinical diagnostic criteria(2016) of the Ministry of Health, Labor and Welfare, a person who has undergone diagnosis of cerebral spinal fluid reduction 8) Until three month's earlier PET examination, persons who are unable to stop taking drug which may affect microglial activation or Chinese medicine with anti-inflammatory effects 9) Until one month prior to the implementation of PET, persons who are unable to stop medicines that may affect microglia activation or high antipyretics analgesic drugs with COX-1 selection system 10) BMI less than 15, more than 30 11) Others who judged inappropriate by the attending physician 12) For healthy subjects, those with a history of anemia, those with chronic fatigue and malaise, those with a history of surgery within six months, those with a history of psychiatric diseases, workers with working over 100 hours per month or shift worker with night shift, person with sleep disorder, person who has been reexamined by health check within 6 months, more than 2 in fatigue performance status
Investigators
Similar Trials
Recruiting
Not Applicable
Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1)Steinerts disease10029299DM1NL-OMON50021Radboud Universitair Medisch Centrum20
Recruiting
Not Applicable
Identification and analysis of biomarkers for the course of demyelinating and inflammatory diseases of the central nervous system, in particular multiple sclerosisDemyelinating and inflammatory diseases of the central nervous system, in particular multiple sclerosisDRKS00031139MPI-NAT1,000
Recruiting
Not Applicable
Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)Coronavirus Disease 19 (COVID-19)U07.1J12J13J14J15J16J17J18COVID-19, virus identifiedViral pneumonia, not elsewhere classifiedPneumonia due to Streptococcus pneumoniaePneumonia due to Haemophilus influenzaeBacterial pneumonia, not elsewhere classifiedPneumonia due to other infectious organisms, not elsewhere classifiedPneumonia in diseases classified elsewherePneumonia, organism unspecifiedDRKS00022871CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover400
Completed
Not Applicable
Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-PROGRESS)U07.1J12J13J14J15J16J17J18COVID-19, virus identifiedViral pneumonia, not elsewhere classifiedPneumonia due to Streptococcus pneumoniaePneumonia due to Haemophilus influenzaeBacterial pneumonia, not elsewhere classifiedPneumonia due to other infectious organisms, not elsewhere classifiedPneumonia in diseases classified elsewherePneumonia, organism unspecifiedDRKS00023277Charité – Universitätsmedizin Berlin, Med. Klinik m. S. Infektiologie und Pneumologie, und Arbeitsbereich Pulmonale Inflammation94
Recruiting
Not Applicable
Biomarker discovery and development of therapy for aortic aneurysmAortic aneurysmJPRN-UMIN000010927Yokohama City University Graduate School of Medicine150